Novo Nordisk launches cheaper Ozempic in South Africa

Novo Nordisk launched a cheaper version of its weight-loss drug Ozempic in South Africa to combat counterfeit products and address high obesity rates. The drug, originally developed for diabetes, is now in high demand, with unregulated alternatives flooding the market due to affordability issues. South Africa has the highest adult obesity rate in Africa, affecting nearly 30% of adults, with women disproportionately impacted.